zinc finger protein 277Genealiases: NRIF4 · ZNF277P
Q-omics provides the consensus-scored ZNF277 profile across patient tissues and cancer cell-line models. ZNF277 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF277 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF277 RNA expression shows 17,995 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where ZNF277 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF277 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF277 survival associations across molecular data types. ZNF277 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF277 RNA expression–survival associations across cancer types. High ZNF277 expression shows unfavorable associations in KICH, ACC and SCLC, but favorable associations in MESO, KIRC and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF277 RNA expression.
This table summarizes ZNF277 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF277. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF277 shows higher tumor expression in HNSC, KIRP, LIHC, COAD, KIRC and CHOL. The HNSC box plot shows higher ZNF277 RNA expression in tumor versus normal tissue (log2 FC = +0.632, t-test p < 0.001).
This table shows molecular features associated with ZNF277 in patient tissues and cancer cell lines. In patient samples, ZNF277 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF277 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
